Results 61 to 70 of about 5,430 (178)

The Impact of Hepatitis C and Socio‐Demographic Variables on Health‐Related Quality of Life in Pakistan: Cross‐Sectional Study

Journal of Viral Hepatitis, Volume 33, Issue 4, April 2026.
ABSTRACT Approximately 8.8 million people are living with chronic hepatitis C virus (HCV) in Pakistan. We assessed factors related to health‐related quality of life (HRQoL) among the general population screened for HCV and calculated the national burden in quality‐adjusted life years (QALYs).
Siwaporn Niyomsri, Aaron G. Lim, Ambreen Arif, Muhammad Asim, Auj Chaudhry, Naheed Choudhry, Aliya Hasnain, Polychronis Kemos, Chris Metcalfe, Asad Choudhry, Saeed Sadiq Hamid, Saad Niaz, Huma Qureshi, Graham R. Foster, Peter Vickerman, Josephine G. Walker, HepFreePak team, Aqsa Ramzan, Atif Saghir, Ejaz Alam, Ghayas Hai, Mohd Saadullah, Muhammad Nabeel Shafqat, Muhammad Sufyan Tahir, Taha Khan   +24 more
wiley   +1 more source

Possible acute rejection associated with the use of the new antihepatitis C virus medications

Avicenna Journal of Medicine, 2019
Hepatitis C virus infection is associated with increased morbidity and mortality. It remains a major challenge for management and treatment, especially in patients with renal transplant.
Khaled Ar Karkout, Saleema Al Sherif, Qutaiba Hussein, Alia Albawardi, Yousef Boobes   +4 more
doaj   +1 more source

Conformational Trajectory of the Molecular Chameleon Grazoprevir From Formulation to Target‐Bound

Chemistry – A European Journal, Volume 32, Issue 8, 23 February 2026.
ABSTRACT Macrocycles represent a promising class of beyond‐rule‐of‐5 (bRo5) therapeutics, capable of targeting proteins traditionally considered undruggable by conventional small molecules. Macrocycles exhibit intrinsic flexibility and often display a “chameleon‐like” ability to adapt to their environment, thereby enhancing their oral bioavailability ...
Lianne H. E. Wieske, Guanhong Bu, Máté Erdélyi, Jan Kihlberg, Tamir Gonen, Emma Rova Danelius   +5 more
wiley   +1 more source

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

, 2015
OBJECTIVE: To evaluate the safety and efficacy of daclatasvir, an HCV NS5A inhibitor with pangenotypic activity, administered with peginterferon-alfa-2a/ribavirin. DESIGN: In this Phase 2b double-blind, placebo-controlled study, treatment-naive adults
Esmat G, BRUNETTO, MAURIZIA ROSSANA, Lawitz, Eric J, Esmat, Gamal, McPhee, Fiona, Zeuzem S, Weiland O, Sievert, William, Pockros, Paul J, Sievert W, Serfaty, Lawrence, Hirschfield GM, Rodriguez Torres M, Everson, Gregory T, Wind Rotolo M, Waked I, Hernandez D, Rustgi VK, Bourlière M, Shafran, Stephen D, Ghesquiere, Wayne, McPhee F, Kwo, Paul Y, Vierling JM, Ghesquiere W, Bräu, Norbert, Schnittman, Steven, Thuluvath PJ, Noviello S, Sulkowski, Mark, Fried, Michael W, Hézode C, Rodriguez-Torres, Maribel, Pol S, Bourlière, Marc, Brunetto, Maurizia R, Pockros PJ, Hirschfield, Gideon M, Serfaty L, Everson GT, Hughes EA, Hézode, Christophe, Yin PD, Bräu N, Hernandez, Dennis, Liu Z, Lawitz EJ, Noviello, Stephanie, Kwo PY, Weiland, Ola, Weis, Nina, Waked, Imam, Liu, Zhaohui, Tatum, Harvey A, Yin, Philip D, Sulkowski M, Thuluvath, Paul J, Fried MW, Tatum HA, Schnittman S., Shafran SD, Weis N, Pol, Stanislas, Rustgi, Vinod K, Hughes, Eric A, Wind-Rotolo, Megan, Vierling, John M, Zeuzem, Stefan   +67 more
core   +1 more source

Predictors of the efficiency of short-term interferon-containing therapy using direct-acting antiviral drugs in patients with chronic hepatitis C virus genotype 1

Терапевтический архив, 2017
Aim. To identify predictors for the high efficiency of short-term interferon-containing antiviral therapy (AVT) using direct-acting antivirals (DAAs) in patients with chronic hepatitis C (CHC) virus (HCV) type 1 (CHC-1). Materials and methods. A total of
K Yu Kokina, A O Bueverov, P O Bogomolov, M V Matsievich   +3 more
doaj   +1 more source

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug Transporters

The Journal of Clinical Pharmacology, Volume 66, Issue 2, February 2026.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug candidate for the treatment of chronic hepatitis C virus infection. Potential drug–drug interactions (DDIs) of bemnifosbuvir as a substrate or perpetrator with regard to ATP‐binding cassette (ABC) and solute carrier (SLC) transporters were evaluated in vitro and in clinical studies ...
Xiao‐Jian Zhou, Alex Vo, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Arantxa Horga, Nancy Agrawal, Janet Hammond   +9 more
wiley   +1 more source

Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals

GMS Ophthalmology Cases, 2016
We report a patient with a bilateral optic anterior ischemic neuropathy as an extrahepatic complication of a chronic hepatitis C (HCV) infection. The patient presented with a bilateral visual acuity loss and bilateral optic disc oedema.
Prud’homme, Sylvie, Nevens, Frederik, Casteels, Ingele   +2 more
doaj   +1 more source

Pre‐Treatment Liver Stiffness Is a Stronger Predictor of Hepatocellular Carcinoma Development Than Post‐Treatment Liver Stiffness After Hepatitis C Virus Eradication

Hepatology Research, Volume 56, Issue 2, Page 161-171, February 2026.
Higher pre‐treatment liver stiffness measurement (LSM) values, rather than post‐treatment values, independently predicts hepatocellular carcinoma after hepatitis C virus eradication, underscoring the need for continued surveillance in patients with elevated baseline LSM.
Takuma Nakatsuka, Ryo Nakagomi, Keisuke Mabuchi, Yuki Matsushita, Tomoharu Yamada, Kazuya Okushin, Tatsuya Minami, Masaya Sato, Koji Uchino, Yotaro Kudo, Mitsuhiro Fujishiro, Kazuhiko Koike, Ryosuke Tateishi   +12 more
wiley   +1 more source

Disrupting Viral Persistence: CRISPR/Cas9‐Based Strategies for Hepatitis B and C Treatment, and Challenges

Journal of Cellular and Molecular Medicine, Volume 30, Issue 1, January 2026.
ABSTRACT Hepatitis B and C viruses (HBV and HCV) remain among the leading causes of liver disease worldwide. Current antiviral drugs, such as nucleotide analogues (NAs), can reduce the replication of new HBV and HCV infections but cannot completely eliminate chronic infections.
Meng‐Fan Li, Akmal Zubair, Safa Wdidi, Shan He   +3 more
wiley   +1 more source

A Refined Model of the HCV NS5A Protein Bound to Daclatasvir Explains Drug-Resistant Mutations and Activity against Divergent Genotypes

, 2016
Many direct-acting antiviral agents (DAAs) that selectively block hepatitis C virus (HCV) replication are currently under development. Among these agents is Daclatasvir, a first-in-class inhibitor targeting the NS5A viral protein. Although Daclatasvir is
Khaled H. Barakat (293854), Morris J. Robins (1651312), Anwar Anwar-Mohamed (1651315), Jack A. Tuszynski (160860), Michael Houghton (339213), D. Lorne Tyrrell (17808)   +5 more
core   +1 more source